| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
AC Immune SA (NASDAQ: ACIU)
ACIU Technical Analysis
5
| As on 9th Jun 2023 ACIU STOCK Price closed @ 2.20 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.56 & Strong Sell for SHORT-TERM with Stoploss of 4.54 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ACIUSTOCK Price
| Open | 2.22 | Change | Price | % |
| High | 2.25 | 1 Day | -0.02 | -0.90 |
| Low | 2.19 | 1 Week | 0.02 | 0.92 |
| Close | 2.20 | 1 Month | 0.32 | 17.02 |
| Volume | 36900 | 1 Year | -2.93 | -57.12 |
| 52 Week High 5.39 | 52 Week Low 1.72 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ACIU Daily Charts |
ACIU Intraday Charts |
Whats New @ Bazaartrend |
ACIU Free Analysis |
|
|
ACIU Important Levels Intraday
| RESISTANCE | 2.32 |
| RESISTANCE | 2.28 |
| RESISTANCE | 2.26 |
| RESISTANCE | 2.23 |
| SUPPORT | 2.17 |
| SUPPORT | 2.14 |
| SUPPORT | 2.12 |
| SUPPORT | 2.08 |
ACIU Forecast April 2024
| 4th UP Forecast | 4.01 |
| 3rd UP Forecast | 3.43 |
| 2nd UP Forecast | 3.07 |
| 1st UP Forecast | 2.71 |
| 1st DOWN Forecast | 1.69 |
| 2nd DOWN Forecast | 1.33 |
| 3rd DOWN Forecast | 0.97 |
| 4th DOWN Forecast | 0.39 |
ACIU Weekly Forecast
| 4th UP Forecast | 3.16 |
| 3rd UP Forecast | 2.85 |
| 2nd UP Forecast | 2.66 |
| 1st UP Forecast | 2.47 |
| 1st DOWN Forecast | 1.93 |
| 2nd DOWN Forecast | 1.74 |
| 3rd DOWN Forecast | 1.55 |
| 4th DOWN Forecast | 1.24 |
ACIU Forecast2024
| 4th UP Forecast | 9.37 |
| 3rd UP Forecast | 7.07 |
| 2nd UP Forecast | 5.65 |
| 1st UP Forecast | 4.23 |
| 1st DOWN Forecast | 0.17 |
| 2nd DOWN Forecast | -1.25 |
| 3rd DOWN Forecast | -2.67 |
| 4th DOWN Forecast | -4.97 |
AC Immune SA ( NASDAQ USA Symbol : ACIU )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ACIU Business Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. Address: Building B, Lausanne, Switzerland, 1015
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service